Northwest Biotherapeutics Inc (QB) (NWBO) Quote

The company is worth $20billion right now in a normal market that was run by an honest exchange . Price is over $30 billion with only a MHRA approval and $75 billion with FDA approval.



good lord. You cant be serious. NWBO has zero revenue that does not change in the months after UK approval. That market cap would be justified with a $ 3- 5 billion revenue and not imaginary revenue that comes from Atlanta's Excel sheet no real reported revenue

Just because a product may or may not have a certain potential doesn't mean it will get to that potential and therefore is allready worth x10 that

Well well well .... Best to Zip it???
Who was right once again?

when almost certainly this OTC company is preparing to wind down.

Yeah ... 210 days - assumably - hit today after MHRA validation for MAA application, for a drug that has been 15 years in a P3 trial, which got the UKs first PIM designation in 2014

https://www.gov.uk/government/news/first-uk-promising-innovative-medicine-designation-awarded

and which got allowed to be used for compassionate use also in 2014

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514134/

... as MHRA do, when they are allowing unsafe not working drugs to be used and paid for by patients.

Yeah ... Advent Bioservices being MIA certified by MHRA in 2023, A CDMO primarily doing the bidding of NWBO, regarding manufactoring DCVax-L and doing biosimilarity testing. Before we begin the swan song about Advent having other customers, then lets just rehash, WHO is responding HOW HIGH, when Linda Powers holds the leash around Advents head and say JUMP.

https://threadreaderapp.com/thread/1632403245963395074.html

You know, Advent ... who went from 13 to now around 120 people in 4 years and now being the UKs highest certified CDMO in cell and gene therapy.

Advent, who have gotten a fairly large portion of NWBOs expenses paid in NWBO shares ... because ... that's what a CDMO would like, knowing the OTC company it supports is heading for bankruptcy?

You, being mr. Picky in the case of anything NWBO, perhaps you need to speed up with the "LOOK MA ... A NEW ARTICLE ABOUT A MICE TRIAL REGARDING GLIOBLASTOMA TREATMENT PERHAPS COMING TO HUMANITY IN AROUND 8-10 YEARS" links, before reality hits you and you yet again have to plan some can kicking of your goal posts, together with your boiler room peers?

Till then ... what is on the FUD menu for today?

Of course not mentioning the manipulation of the share price, the spoofing, the lawsuit, the evidence collected.

No let's keep this to management not providing guidance to poor retail. A guidance who I believe YOU and your peers are the stakeholders who REALLY crave guidance.

Just look at the pathetic complaint "someone" wrote last year, in order to perhaps get Advent to "spill the beans" about their process.

https://ico.org.uk/media/action-weve-taken/decision-notices/2023/4025017/ic-195519-t0x4.pdf

I think the funny part is the Judas disciples, who are desperate for "guidance", that is not just todays FUD transcript from .... who ever are above them in the cabal hierarchy.

Well you might be correct. According to Google, the patent for Merck's cancer drug Keytruda is scheduled to expire in the United States in 2028. This means that Merck will face competition from biosimilar copycat medicines after that date.
However, It doesn’t really change the optics. If Merck’s CEO lets the opportunity pass, to extend their patent until 2034, the board and Shareholders will be brutal.

Again, do the math 30 Billion dollars of revenue in today’s dollars for 8? Years. Would equate to a Share Price of what?

I'm sorry, but the 2026 date keeps getting repeated. The way I read it keytruda patent expires 2028

FEMIKE- Keytruda sales during 2023 totaled $25.01 billion, up 19 percent from $20.94 billion in 2022. The Patent on Keytruda expires 2026. How much will Merck pay to extend their patent on their blockbuster? By next year revenue due to Keytruda will exceed 30 BILLION DOLLARS. NWBO will cut a deal with Merck. To this you may add the value of Flaskworks, DCVax-D, and other Combination therapies. 30 billion is the starting point.

You do the MATH. It has lots of zeros

Some things never change. I’m of the opinion there will never be peace in the world especially the Middle East. Yes, I have lived there.

The simple fact is that any non-insider individuals or funds can and might currently own or acquire up to some 60M shares (5% of total issued) with no obligation hence no reason to file said ownership with the SEC.

Judas was a disciple. All the disciples and Jesus were Jewish. Aside from Judas (perhaps), they were trying to move global society away from ideas like an eye for an eye, and instead, do unto to others as you would have others do unto you.

They were trying to promote multicultural tolerance, being good Samaritans, hate the sin but not the sinner, forgiveness and mercy.

They tried anyway. It’s pretty violent out there right now though.

Disciple or Judas?

It was just a short thought.

SmallCapStockAlert Sure you did. .LOL

I think approval alone is largely priced in.

Are you kidding me? You figured it out yourself or someone told you. Did you finish the homework assignment? Finish the homework and then you come back on board to have a serious talk with the NWBO longs.

Yes I would have loved to be in the ROI phase yesterday but nothing in the due diligence says that each day isn’t a day closer and tomorrow could be the day or not, but the MHRA will decide to approve the MAA or not and most scenarios suggest it’s imminent.

LC,

Thanks for posting your helpful predictions.

“…almost certainly preparing to wind down”

Sure, that seems obvious too! 😶





https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

https://www.nature.com/articles/s41467-024-48073-y


https://thejns.org/caselessons/downloadpdf/view/journals/j-neurosurg-case-lessons/8/2/article-CASE24112.pdf

Lot of investors are waiting for that to eventually materialize and hopefully not in a year or two . More like yesterday .

Your perspective is a good example of why some pharma’s fade because they don’t recognize and invest in sound science and manufacturing potential. Your loss. Next bidder please.

Nothing is priced in due to the complete manipulative control of the sp in my opinion!!!

The sp is artificially maintained imo, and it will continue until catalysts that break the alleged grip materialize!

The potential catalysts include things the manipulators can resist, however there are changes that the manipulators can’t overcome, such as M&A activity that can catch shorts with their pants down.

How hard would it be to link up nwbo with one or two other entities? I would think not hard. LP has alluded to the “right” timing a number of times in her recent communications.

That’s my opinion and I’m sticking with it

I’m of the belief that LP and nwbo are operating with business strategy and goals defined.

Evidently the moat is being built around dendritic cell platform technologies, including how to manufacture in closed systems, which is going to be a tremendous advantage for nwbo.

The recent in-licensing deal, with excellent terms for nwbo, rounds out and complements the DCVax platform, and implies a belief in nwbo’s ability and potential to manage the combined assets and ecosystem!!!

Despite the efforts of nwbo’s foes and stock manipulators the steady (and yes slow) execution is proceeding to DCVax L first approval and well beyond. LP made it a point to discuss combination treatments and DCVax Direct! The moat is around the broader dendritic cell “franchise.”

The sun will come up, tomorrow!!!

You're right management is senior.

Spoke with senior management and this may be a great combination trial for DCVAX. Ropidoxuridine makes radiation work like it is on steroids and it improves safety. DC VAX and Ropidoxuridine could be the perfect combo for GBM and many other cancers. https://richardacavalli.wixsite.com/greenplanetmicrocaps/nexgen-cancer-radiation

The odds of your scenario I put at about .01%

Might be a few days before other news is presented, but this (your view) sounds exceptionally unlikely.

I think you post in this manner in the hopes that nw see your post and act accordingly.

They won't do what you want, but the ultimate result in my view is we will get supplemental news, just not because the concept was discussed on ihub.

. Price is over $30 billion with only a MHRA approval and $75 billion with FDA approval.

Please show your work. I’d love to know how you arrived at these numbers.

LP could've built shareholders a public CDMO empire but instead she slowly built private companies with no serious access to public cash except for what retail could provide.

There it is!
One last “disciple” comment before calling it quits?!?

Funny part is disciples are waiting for their day in the sun when almost certainly this OTC company is preparing to wind down.

Asset is only worth what someone is willing to pay for it , not what you think it should be .

The company is worth $20billion right now in a normal market that was run by an honest exchange . Price is over $30 billion with only a MHRA approval and $75 billion with FDA approval.

Agree

Is that what your collusively manipulative bosses are telling you?

Do you think the potential approval has already been more or less priced in, especially considering the stock is being diluted?

I’ve been saying this for a while.

If we get approval news before anything else, and it doesn’t come with some sort of excellent guidance/other news, we are in for an unpleasant response. $0.50’s would be a good close day of, and I don’t have a red day off the table.

So yes, I think approval alone is largely priced in. NWBO has simply taken too long to advance this.

marty,

Still no increase in your position? When was the last time you were loading? Two years or three years ago? With so many input over the past a couple of years, your understanding about the company has not evolved? IMO, loading as many as you can and then having a happy life ever after.

You do know a professor by the name: Yves LEVY. He wrote plenty papers on CYT107. He just published a paper on HIV vaccine which is based on dendritic cell and poly-iclc is used as adjuvant. Read it and your input will be appreciated.

Recall what Oncovir president talked about HIV in one of articles. Today the Lancet published a paper on the results from the trial on HIV vaccine development. Note that the vaccine is based on dendritic cell and poly-iclc is used as adjuvant. Again the $NWBO longs focus on the… pic.twitter.com/rkDQMmf7ow— d_stock (@d_stock07734) October 2, 2024

You are asking the wrong questions bruh!
You invested in NWBOs success?

Guess you’re still technically “invested” if you short, thus I included “success”.

I don’t think it will take that long .
For some weird reason if it does , some here will say it was always obvious that approval was supposed to come at that time . If any one thought it was coming sooner is naive and shouldn’t be investing in dev stage biotech .

I wonder what the narrative will be next year when we get past Q2 2025 and still see no sign of approval. Some will say there’s no way we won’t get approval by then, but hey, some said there was no way we’d get approval after fall 2024.

Point taken.

Hope this U.S. continuation patent application perspective helps in context of what appears to be going on with combination trial.

I’ve edited this down.


ChatGPT

People may abandon patent applications for several reasons, often related to strategic business decisions, costs, or changes in market conditions. Here are some common reasons why this occurs, particularly in the context of replacing them with continuation applications:



3. **Improvement of Claims**: A continuation patent application allows inventors to pursue additional claims based on the original application. If the original application is not strong or if new developments arise, inventors may abandon it in favor of a continuation that better captures the desired scope of protection.



In summary, abandoning an application and replacing it with a continuation is often a strategic decision aimed at enhancing the chances of obtaining a patent that better aligns with the applicant's current needs and objectives.


(Again, remembering Europe’s respective countries and a few other countries already actually grated the combination patent)

Right, and I do it too, but don’t forget to say patent applications when you don’t mean patent. It’s easy to leave application off and confuse.

Technically, you are correct. But if the "abandoned" applications were replaced/upgraded with a continuation patent application, then the combo patent is still being pursued. In my mind, "still being pursued via a continuation patent application" is similar to "not abandoned". Perhaps "NWBO patents are still being pursued" would have been more accurate.

Thanks for the correction. I don't want to confuse anyone.

As the emotional low IQs obsess over management, I'm reminded of what Poorman once said, and it's perfectly fitting for these times, "Everyone's lying." So true:

Did world renowned scientist Eliezer Masliah make up research on Parkinson’s and Alzheimer’s diseases?

This reminds me of Theranos Founder CEO Elizabeth Holmes, but on a far bigger scale.

Holmes is now in prison

"His output, as well as the number of citations to his papers,… https://t.co/ONaXki0SZX pic.twitter.com/0ze6R1sBUs— kristen shaughnessy (@kshaughnessy2) October 1, 2024

The U.S. parent combo patent applications were abandoned, but there are two unpublished continuation patent applications pending.

Right now, Henry can correct me if I’m wrong, Europe(a continent obviously), Israel, Ireland, Hong Kong, maybe Japan and if memory serves Switzerland and a few other countries have granted the combination patent.

No, tomorrow is 210 days since March 7.

Friday is 210. So now we are our second 60 day.......
December-January 2025 I guess

Thank you so much for the info, CrashOverride. Indeed, the US combo patent has not been abandoned!

Exactly.

If 150 days accelerated + 60 days clock off, then yes.

Or

If 210 days non-accelerated and no clock off (if no rfi) then no.

Or

(150 day + 60 back and forth) Hybrid accelerated
There is a decent chance there was no formal rfi, but informal back and forth, which could make the 60 days clock a little hard to label.

Or

Something else.

Did you add in clock off days?

ofcourse I meant patent application I assumed that was automatically understood

Yes I quoted you
So the same patent application as what you were talking about in your post of January 25, 2024 11:14:36 AM

thanks

lol. You wrote a post but forgot the writing below the link was my quote.


Do you mean patent or patent application? If you mean patent application, the facts have been laid out in this thread.

is this the same patent?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173701735

Okay. Are you following? NWBO (assignee) has a joint patent application with UCLA (assignee) and Revimmune (assignee) and NIH/NCI (assignee, assigned by NWBO)

The combination trial with DCVax-l, Poly-ICLC and Keytruda has the following sponsors.

Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Phase One Foundation
Oncovir, Inc.

The combination patent application is temporarily abandoned, but, according to your buddy Exwannabe, whom I believe in this case, NWBO filed a timely continuation.

Do you know one of the reasons these assignments occur? Because of prior agreements between the parties. Do you know who is pursuing the patent? NWBO. Do you know why the other parties allow NWBO to pursue the patent? Because of prior agreements.

When the combination trial began, it was an outcome of joint effort resulting in a joint patent application.

LP is an expert in intellectual property. You, are not